Barrett H. Childs - Clinical Development, Bayer HealthCare Pharmaceuticals Inc

基本信息

浏览量：36

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 122 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen

Peter N. Morcos,Jonathan Moss, Josh Veasy,Florian Hiemeyer,Barrett H. Childs,Dirk Garmann

CLINICAL PHARMACOLOGY & THERAPEUTICSno. 5 (2024): 1092-1104

引用0浏览0引用

Copanlisib Population Pharmacokinetics from Phase I-III Studies and Exposure-Response Relationships in Combination with Rituximab

Peter N. N. Morcos,Jonathan Moss,Rupert Austin,Florian Hiemeyer,Pier Luigi Zinzani,Vita Beckert,Lidia Mongay Soler,Barrett H. H. Childs,Dirk Garmann

CPT pharmacometrics & systems pharmacologyno. 11 (2023): 1666-1686

引用1浏览0WOS引用

Pharmacometrics (pmx) approach to support pediatric dosing for the pan-pi3k inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors

P. Morcos,J. Schlender,R. Burghaus, J. Moss, A. Lloyd, F. Huang,B. Childs,M. Macy,J. Reid,J. Chung,D. Garmann

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023): S68-S68

引用0浏览0引用

Pooled Exposure-Response (ER) and Quantitative Benefit/Risk (B/R) Analyses Support the Approved Copanlisib Intermittent Dosing Regimen

Peter N. Morcos,Jonathan Moss,Charles Phelps,Florian J. R. Hiemeyer,Barrett H. Childs,Martin Dreyling,Pier Luigi Zinzani,Dirk Garmann

Blood (2023): 6156

引用0浏览0引用

Model‐informed Approach to Support Pediatric Dosing for the Pan‐pi3k Inhibitor Copanlisib in Children and Adolescents with Relapsed/refractory Solid Tumors

Peter N. Morcos,Jan Schlender,Rolf Burghaus,Jonathan Moss, Adam Lloyd,Barrett H. Childs,Margaret E. Macy, Joel M. Reid,John Chung,Dirk Garmann

CTS-CLINICAL AND TRANSLATIONAL SCIENCEno. 7 (2023): 1197-1209

引用0浏览0WOS引用

Safety and Antitumor Activity of Copanlisib in Japanese Patients with Relapsed/refractory Indolent Non-Hodgkin Lymphoma: a Phase Ib/II Study

Noriko Fukuhara,Dai Maruyama,Kiyohiko Hatake,Hirokazu Nagai,Shinichi Makita,Kenjiro Kamezaki,Toshiki Uchida,Shigeru Kusumoto,Junya Kuroda,Chisako Iriyama,Masamitsu Yanada,Norifumi Tsukamoto,Youko Suehiro,Hironobu Minami,Jose Garcia-Vargas,Barrett H. Childs,Masanobu Yasuda, Shigeo Masuda,Toshiaki Tsujino, Yui Terao,Kensei Tobinai

INTERNATIONAL JOURNAL OF HEMATOLOGYno. 1 (2023): 100-109

引用0浏览0WOS引用

Abstract CT082: Next-generation Sequencing (NGS) and Cytokine Assessment from a Phase III Study of Copanlisib in Combination with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma (inhl) - Associations with Survival Endpoints

Shalini Chaturvedi,Anke Weispfenning, David Bauer, Rong Du,Tine Descamps,Sara Bellinvia, Teresa Lunt,Lidia Mongay Soler,Barrett H. Childs,Pier Luigi Zinzani

CANCER RESEARCH（2023）

引用0浏览0引用

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Pier Luigi Zinzani,Muhit Ozcan,Marcelo Capra,Armando Santoro,Panayiotis Panayiotidis,Krimo Bouabdallah,Wojciech Jurczak,Charles Phelps,Florian J. R. Hiemeyer,Lidia Mongay Soler,Jose Garcia-Vargas,Barrett H. Childs,Georg Lenz,Matthew J. Matasar,Martin Dreyling

Blood（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn